ABVC BIOPHARMA, INC. — SEC Form D Filing

ABVC BIOPHARMA, INC. filed an SEC Form D on November 10, 2026, reporting $3.39M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
November 10, 2026
Amount reported
$3.39M
Round stage
Series B+
Industry
Biotechnology
Website
https://abvcbiopharma.com/

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: NEVADA

Problem

Patients face difficult-to-treat conditions across central nervous system disorders (such as major depressive disorder and adult ADHD), diverse cancers, and eye conditions requiring vitreoretinal surgery.

Solution

ABVC BioPharma develops botanical-derived therapeutic candidates—including PDC-1421-based treatments for depression and ADHD—as well as medical technologies like Vitargus, a biodegradable hydrogel vitreous substitute for eye surgery.

Why now

Growing regulatory and clinical frameworks now allow standardized botanical compounds and advanced hydrogel biomaterials to pass rigorous clinical trial benchmarks.

Verdict

Investors funded this round because a sub-four-million-dollar check offered cheap optionality on late-stage phase transitions across both CNS and ophthalmology, not because they bought into botanical extraction as a coherent platform strategy. Underwriting this meant betting that at least one disparate asset could produce partnering data before the balance sheet evaporated. Upside was strictly capped by the conglomerate structure, which split scarce capital across unrelated modalities and signaled to institutional syndicates that the company lacked the conviction to focus on a single lead program.

Source: SEC EDGAR Form D filing